We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Immunocore to Present at 32nd Annual JP Morgan Healthcare Conference
News

Immunocore to Present at 32nd Annual JP Morgan Healthcare Conference

Immunocore to Present at 32nd Annual JP Morgan Healthcare Conference
News

Immunocore to Present at 32nd Annual JP Morgan Healthcare Conference

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Immunocore to Present at 32nd Annual JP Morgan Healthcare Conference"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Immunocore Limited has announced that it will present at the 32nd annual JP Morgan Healthcare Conference on Thursday 16 January 2014 at 11:30 am (Pacific Time) at the Westin St Francis Hotel, San Francisco.

James Noble, Chief Executive Officer, will present a corporate update and data from Immunocore’s most advanced ImmTAC programme, IMCgp100, for the treatment of late stage melanoma.

Phase I testing was completed in late 2013, with promising early signs of efficacy indicated, and the company has initiated a Phase IIa trial in the UK and USA designed to optimize the dosing regimen and maximize the efficacy of IMCgp100.

Last week Immunocore has announced its third partnership deal in six months - an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca.

Both companies will research and develop novel cancer therapies using Immunocore’s ImmTAC technology.

Immunocore’s novel bi-specific biologics platform exploits the power of the body’s own immune system to find and kill diseased cells. ImmTACs direct a patient’s T cells to specifically destroy only the cancerous cells, avoiding damage to healthy cells.

Immunocore also has major discovery collaborations ongoing with leading pharmaceutical companies Genentech and GlaxoSmithKline.

Advertisement